VIDEO: Supplemental aflibercept did not influence outcomes of EYP-1901 in wet AMD
In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Carl D. Regillo, MD, discusses the impact of supplemental aflibercept on eyes with wet age-related macular degeneration treated with EYP-1901.
According to Regillo, a subgroup analysis of the phase 2 DAVIO 2 trial looked at the effect of supplemental injections after treatment with EYP-1901 (EyePoint Pharmaceuticals) on vision and anatomic outcomes.
“What we did is we compared eyes without supplements to the entire patient population in the EYP arms and did not see a difference, both in BCVA outcomes or OCT anatomic outcomes,” he said. “We can conclude that the supplemental injections that were performed in about a third of the patients in the EYP arms didn’t influence the outcomes.”
Regillo also discussed plans for a phase 3 registration trial on EYP-1901.
Collapse
Regillo CD. The DAVIO 2 trial: Subgroup data from a phase 2, multicenter study of a single injection of EYP-1901 (vorolanib in the Durasert E technology) vs aflibercept for previously treated wet age-related macular degeneration. Presented at: Angiogenesis, Exudation, and Degeneration 2024; Feb. 3, 2024 (virtual meeting).
Read more about